Nanoliposomal VEGF-R2 peptide vaccine acts as an effective therapeutic vaccine in a murine B16F10 model of melanoma.
Melanoma
Nanoliposomal vaccine
Peptide vaccine
VEGFR-2
Journal
Cancer nanotechnology
ISSN: 1868-6958
Titre abrégé: Cancer Nanotechnol
Pays: Austria
ID NLM: 101516978
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
03
2023
accepted:
31
05
2023
medline:
19
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
The vascular endothelial growth factor receptor-2 (VEGFR-2) plays an important role in melanoma development and progression. Peptide vaccines have shown great potential in cancer immunotherapy by targeting VEGFR-2 as a tumor-associated antigen and boosting the immune response against both tumor cells and tumor endothelial cells. Despite this, the low efficiency of peptide vaccines has resulted in moderate therapeutic results in the majority of studies. Enhancing the delivery of peptide vaccines using nanoliposomes is an important strategy for improving the efficacy of peptide vaccines. In this regard, we designed VEGFR-2-derived peptides restricted to both mouse MHC I and human HLA-A*02:01 using immunoinformatic tools and selected three peptides representing the highest binding affinities. The peptides were encapsulated in nanoliposomal formulations using the film method plus bath sonication and characterized for their colloidal properties. The mean diameter of peptide-encapsulated liposomes was around 135 nm, zeta potential of - 17 mV, and encapsulation efficiency of approximately 70%. Then, vaccine formulations were injected subcutaneously in mice bearing B16F10-established melanoma tumors and their efficiency in triggering immunological, and anti-tumor responses was evaluated. Our results represented that one of our designed VEGFR-2 peptide nanoliposomal formulations (Lip-V1) substantially activated CD4 Our findings suggest that the nanoliposomal formulation containing VEGFR-2 peptides could be a promising therapeutic vaccination approach capable of eliciting strong antigen-specific immunologic and anti-tumor responses. The online version contains supplementary material available at 10.1186/s12645-023-00213-7.
Sections du résumé
Background
UNASSIGNED
The vascular endothelial growth factor receptor-2 (VEGFR-2) plays an important role in melanoma development and progression. Peptide vaccines have shown great potential in cancer immunotherapy by targeting VEGFR-2 as a tumor-associated antigen and boosting the immune response against both tumor cells and tumor endothelial cells. Despite this, the low efficiency of peptide vaccines has resulted in moderate therapeutic results in the majority of studies. Enhancing the delivery of peptide vaccines using nanoliposomes is an important strategy for improving the efficacy of peptide vaccines. In this regard, we designed VEGFR-2-derived peptides restricted to both mouse MHC I and human HLA-A*02:01 using immunoinformatic tools and selected three peptides representing the highest binding affinities. The peptides were encapsulated in nanoliposomal formulations using the film method plus bath sonication and characterized for their colloidal properties.
Results
UNASSIGNED
The mean diameter of peptide-encapsulated liposomes was around 135 nm, zeta potential of - 17 mV, and encapsulation efficiency of approximately 70%. Then, vaccine formulations were injected subcutaneously in mice bearing B16F10-established melanoma tumors and their efficiency in triggering immunological, and anti-tumor responses was evaluated. Our results represented that one of our designed VEGFR-2 peptide nanoliposomal formulations (Lip-V1) substantially activated CD4
Conclusion
UNASSIGNED
Our findings suggest that the nanoliposomal formulation containing VEGFR-2 peptides could be a promising therapeutic vaccination approach capable of eliciting strong antigen-specific immunologic and anti-tumor responses.
Supplementary Information
UNASSIGNED
The online version contains supplementary material available at 10.1186/s12645-023-00213-7.
Identifiants
pubmed: 37333490
doi: 10.1186/s12645-023-00213-7
pii: 213
pmc: PMC10264216
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that there is no competing financial interests or personal relationships that could influence the work reported in this research.
Références
Semin Oncol. 2007 Dec;34(6):555-65
pubmed: 18083379
Cancer Sci. 2010 Feb;101(2):433-9
pubmed: 19930156
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17463-8
pubmed: 19805168
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):313-322
pubmed: 30776401
Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):499-507
pubmed: 17439422
J Transl Med. 2013 Apr 11;11:97
pubmed: 23578144
Eur J Pharm Sci. 2018 Jul 1;119:159-170
pubmed: 29660463
J Biol Chem. 1959 Mar;234(3):466-8
pubmed: 13641241
Pharmaceutics. 2019 Nov 15;11(11):
pubmed: 31731667
Curr Opin Immunol. 2017 Apr;45:1-7
pubmed: 27940327
Biochem Cell Biol. 2021 Aug;99(4):435-446
pubmed: 33395361
Eur J Cancer. 2022 Jul;170:236-255
pubmed: 35570085
Int J Pharm. 2022 Feb 5;613:121396
pubmed: 34942328
Nat Immunol. 2002 Nov;3(11):999-1005
pubmed: 12407407
Int J Pharm. 2015 Nov 10;495(1):162-170
pubmed: 26302860
J Cell Physiol. 2018 Jul;233(7):5189-5199
pubmed: 29215747
Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213
pubmed: 17324579
J Biomed Biotechnol. 2010;2010:
pubmed: 20706612
Lancet. 2001 Jun 2;357(9270):1777-89
pubmed: 11403834
Pharmaceutics. 2016 Mar 10;8(1):
pubmed: 26978390
Hum Pathol. 2010 Mar;41(3):375-84
pubmed: 20004943
Pharmaceutics. 2020 Nov 04;12(11):
pubmed: 33158166
Br J Cancer. 2013 Apr 2;108(6):1260-6
pubmed: 23470466
Angew Chem Int Ed Engl. 2009;48(23):4146-9
pubmed: 19425026
J Drug Target. 2018 Apr;26(4):365-372
pubmed: 28972792
Iran J Basic Med Sci. 2020 Aug;23(8):1065-1077
pubmed: 32952954
Immunotargets Ther. 2018 Jun 07;7:35-49
pubmed: 29922629
Vaccine. 2020 Jul 31;38(35):5665-5677
pubmed: 32653275
Cell Mol Immunol. 2013 Nov;10(6):490-6
pubmed: 23954948
J Transl Med. 2014 Apr 03;12:84
pubmed: 24708624
J Control Release. 2021 Nov 10;339:235-247
pubmed: 34592386
Int Immunopharmacol. 2020 Aug;85:106603
pubmed: 32485357
Curr Opin Biotechnol. 2020 Dec;66:113-122
pubmed: 32745889
Int Immunopharmacol. 2021 Sep;98:107833
pubmed: 34352472
BMC Cancer. 2020 Mar 12;20(1):196
pubmed: 32164575
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):498-504
pubmed: 15701833
Nanoscale Res Lett. 2013 Feb 22;8(1):102
pubmed: 23432972
J Transl Med. 2014 Mar 10;12:63
pubmed: 24612787
Life Sci. 2022 Feb 15;291:120294
pubmed: 34998838
Curr Opin Pharmacol. 2019 Aug;47:20-26
pubmed: 30831470
Int J Nanomedicine. 2017 Feb 14;12:1251-1264
pubmed: 28243087
J Mater Chem B. 2020 Feb 14;8(6):1093-1107
pubmed: 31960007
Int J Oncol. 2012 Oct;41(4):1297-304
pubmed: 22842485
J Control Release. 2019 Jun 10;303:223-236
pubmed: 30999007
Discov Med. 2015 Apr;19(105):293-301
pubmed: 25977192
Eur J Pharmacol. 2021 Dec 5;912:174565
pubmed: 34656608